The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines

被引:9
|
作者
Ding, Weiyue [1 ]
Wang, Chong [1 ]
Narita, Yohei [1 ]
Wang, Hongbo [1 ]
Leong, Merrin Man Long [1 ]
Huang, Alvin [1 ]
Liao, Yifei [1 ]
Liu, Xuefeng [2 ]
Okuno, Yusuke [3 ]
Kimura, Hiroshi [4 ]
Gewurz, Benjamin [1 ]
Teng, Mingxian [5 ]
Jin, Shuilin [6 ]
Sato, Yoshitaka [4 ]
Zhao, Bo [1 ]
机构
[1] Harvard Med Sch, Div Infect Dis, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA
[3] Nagoya City Univ, Dept Virol, Grad Sch Med, Nagoya, Aichi, Japan
[4] Nagoya Univ, Dept Virol, Grad Sch Med, Nagoya, Aichi, Japan
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat & Bioinformat, Tampa, FL USA
[6] Harvard Med Sch, Precis Neurol Program, Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
3D genome organization; episome; Epstein-Barr virus; latency; DNA-REPLICATION; EFFICIENT; LYMPHOMA; EBV; SEGREGATION; LATENCY; NK;
D O I
10.1128/jvi.00739-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARE1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes similar to 200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS
    SCHUSTER, V
    KRETH, HW
    MONATSSCHRIFT KINDERHEILKUNDE, 1991, 139 (07) : 396 - 400
  • [32] Epstein-Barr virus-associated lymphoproliferative disorders
    Rezk, Sherif A.
    Weiss, Lawrence M.
    HUMAN PATHOLOGY, 2007, 38 (09) : 1293 - 1304
  • [33] Outcome of Epstein-Barr virus-associated primary breast cancer
    Mazouni, Chafika
    Fina, Frederic
    Romain, Sylvie
    Ouafik, L'Houcine
    Bonnier, Pascal
    Martin, Pierre-Marie
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 295 - 298
  • [34] The paradox of Epstein-Barr virus-associated hepatitis
    Negro, F
    JOURNAL OF HEPATOLOGY, 2006, 44 (05) : 839 - 841
  • [35] Targeting Epstein-Barr Virus-Associated Lymphomas
    Nikiforow, Sarah
    LaCasce, Ann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 830 - 832
  • [36] Immunotherapy for Epstein-Barr virus-associated tumors
    Comito, MA
    Sun, Q
    Lucas, KG
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 1981 - 1987
  • [37] IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-ASSOCIATED MALIGNANCIES
    Long, Heather M.
    Parsonage, Gregory
    Fox, Christopher P.
    Lee, Steven P.
    DRUG NEWS & PERSPECTIVES, 2010, 23 (04) : 221 - 228
  • [38] Epstein-Barr virus-associated gastric cancer in a patient with dermatomyositis
    Yamashita, K
    Hosokawa, M
    Hirohashi, S
    Arimura, Y
    Endo, T
    Denno, R
    Ikeda, T
    Imai, K
    INTERNAL MEDICINE, 2001, 40 (02) : 96 - 99
  • [39] Breast cancer: a new Epstein-Barr virus-associated disease?
    Magrath, I
    Bhatia, K
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (16): : 1349 - 1350
  • [40] Clinical Importance of Epstein-Barr Virus-Associated Gastric Cancer
    Nishikawa, Jun
    Iizasa, Hisashi
    Yoshiyama, Hironori
    Shimokuri, Kanami
    Kobayashi, Yuki
    Sasaki, Sho
    Nakamura, Munetaka
    Yanai, Hideo
    Sakai, Kohei
    Suehiro, Yutaka
    Yamasaki, Takahiro
    Sakaida, Isao
    CANCERS, 2018, 10 (06)